Michael Heltzen appointed as CEO bringing 20 years of global commercial leadership experience and a track record of successful launches and exits- Additional industry veterans join in key roles including business development, finance, and communications
"
Prior to joining Invizyne,
"Invizyne’s SimplePath™ platform represents the first biomanufacturing technology that I have come across that overcomes the issues of other cell-based synthetic biology approaches,” said Michael Helzten, CEO of Invizyne. “By using cell-free enzyme systems to produce biochemicals, we believe Invizyne can also significantly create new useful drugs and chemicals that can be commercially produced at competitive prices. I believe that Invizyne can become a leading biomanufacturing company by becoming the leading developer of cell-free enzymatic pathway solutions.”
Leadership Team Expansion
In recent months, the following experienced industry leaders also joined Invizyne’s leadership team:
Michael Burns , Vice President of Energy Transition: As previously announced,Mr. Burns brings two decades worth of business strategy and development, global licensing, project development, and project finance expertise in the sustainable energy and synthetic biology industries to Invizyne, including roles at Novozymes, BP’s Advanced Bio-Products unit, andVerenium Corporation , which was acquired by BASF.Fouad Nawaz , Vice President of Finance: With a background and expertise in corporate finance,Mr. Nawaz has pursued his career in the electronics industry and worked to shape corporate strategy and operational efficiency across global organizations, most recently atFulham Co Inc. Zachary Karl , Ph.D, Vice President of Business Development: With a robust expertise in synthetic biology and business development,Dr. Karl has spent the last decade shaping the strategic and operational landscapes in biotech, including pivotal roles at Ginkgo Bioworks Holdings, Inc. (DNA), POET Technologies Inc. (POET), and SAB Biotherapeutics, Inc. (SABS).- Lasse H. Görlitz, Vice President of Communications: With a background as a European pioneer in data-driven marketing, Mr. Görlitz has spent the past 20 years developing and executing branding, positioning, and communications in life sciences, biotech, and AI, including successful projects with CLC bio, Corti.ai, wusaa, Cardea Bio, Limmi, as well as heading a global rebranding of QIAGEN (QGEN).
Proposed Offering and Listing on Nasdaq
In
As a MDB “Big Idea” Company, the broker dealer subsidiary of MDB intends to give preference to holders of MDB Class A Shares, after which it will give preference to the other beneficial shareholders of MDB. To the extent these foregoing groups do not purchase all the offered shares, then shares will be sold to other persons giving an indication for purchase of shares through their respective brokers or dealers.
A registration statement relating to these securities has been filed with the
A copy of the prospectus related to the offering and included in the registration statement, when available, may be obtained by visiting the
About Invizyne Technologies, Inc.
Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in
For more information, please visit www.invizyne.com
Media contacts:
Lasse Görlitz, VP of Communications
(858) 319-7135
press@invizyne.com
Investor Relations Contact: IR@invizyne.com
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.
Source:
2024 GlobeNewswire, Inc., source